

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 2715

Title: NONINFECTIOUS INTERSTITIAL LUNG DISEASE DURING INFLIXIMAB THERAPY: CASE REPORT AND LITERATURE REVIEW

Reviewer code: 00039386

Science editor: Wang, Jin-Lei

Date sent for review: 2013-03-12 12:33

Date reviewed: 2013-04-02 19:07

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

COMMENTS TO AUTHORS

Dr Caccaro and colleagues report a case of interstitial lung disease associated to infliximab therapy with a brief review of the actual knowledge and underline the increasing reports of pulmonary abnormalities in patients with inflammatory bowel diseases. On the other hand, reports of lung toxicity associated to TNF-alpha antagonists are recently appearing, especially in the rheumatology literature. Interstitial disease has been described also in patients treated with Adalimumab, and few cases have been also reported in UC patients treated with IFX, but associated with other medications (immunosuppressive, mesalazine).